Alzheimer's Disease Trial, Completed NCT00880555 Sponsor: VA Office of Research and Development Condition: Alzheimer's Disease
Back to Alzheimers Disease

Trial results

AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

According to the results reported on ClinicalTrials.gov, this trial enrolled 78 people across several groups: 23 people with a non-dementia memory disorder, 40 people in a control group (people without memory problems), 11 people with mild Alzheimer's disease, and smaller numbers in three additional categories (2 people classified as CIND, 1 person classified as intoxicated, and 1 person with a non-Alzheimer's dementia). The trial was measuring financial capacity — that is, people's ability to understand and handle financial tasks and concepts — using a tool called the Financial Capacity Instrument (FCI). This tool gives a score out of 191, where a higher score means a greater ability to manage financial matters. Only the three main groups contributed to the primary outcome results. The reported data shows FCI scores across what appear to be three separate time points or measurement occasions for the three main groups. In the first set of measurements, the control group scored 164.0 out of 191, the non-dementia memory disorder group scored 147.3, and the mild Alzheimer's disease group scored 123.3. In the second set, the control group scored 179.0, the non-dementia memory disorder group scored 150.8, and the mild Alzheimer's disease group recorded a score of 0 (meaning no data was reported for that group at that time point). In the third set, the control group scored 163, the non-dementia memory disorder group scored 93, and again no data was reported for the mild Alzheimer's disease group. It is worth noting that not all participants completed the study — for example, only 13 of the 23 people in the non-dementia memory disorder group and 23 of the 40 control participants finished, and the data does not explain the reasons for non-completion. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.

Alzheimer's Disease Trial, Completed

NCT00880555
Completed Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You can be a veteran or a non-veteran
  • You must be between 50 and 89 years old
  • You have either normal memory and thinking, mild memory problems (MCI), or early-stage Alzheimer's disease
  • You speak English
  • You are right-handed
  • You have good enough vision and hearing to take part in tests
  • You are willing and able to have an MRI scan
  • You are in stable physical and mental health
  • You do not have any other brain conditions, such as a brain tumor, Parkinson's disease, or a major stroke

Who may not be able to join:

  • You are currently pregnant
  • You are unable to have an MRI scan, for example because you have metal in your body or because you feel very uncomfortable in small, enclosed spaces (claustrophobia)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Completed
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 April 2009
Est. completion
1 May 2014

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

FCI Score at Follow-up

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov